Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 11:00PM GMT
Release Date Price: $22.48 (+7.35%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. It's my pleasure today to introduce Eric Dube, CEO of Travere Therapeutics.

Eric, would you like to start off with some opening remarks and then we can get into Q&A?

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Sure. Well, first of all, thank you for hosting us today. And I would encourage all of you to take a look at our investor deck on our website for forward-looking statements.

What I can say is, we're in a very exciting time of growth for Travere Therapeutics as we look to bring our lead pipeline asset sparsentan to market, as well as to advance an earlier-stage clinical asset. We're a company that's based in San Diego and exclusively focused on rare disease with a particular focus on rare kidney, liver and metabolic disease.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot